Oxford Nanopore secures Fed Circ victory in PacBio DNA suit
13-05-2021
Pacific Biosciences and Oxford Nanopore settle patent claims
09-05-2018
Duncan_Andison / iStockphoto.com
The European Patent Office (EPO) has revoked a patent held by a US biotechnology company, Pacific Biosciences, after its UK-based rival Oxford Nanopore Technologies challenged the validity of the patent.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Pacific Biosciences, Oxford Nanopore, patent infringement, patent validity, nucleic acid, DNA, European Patent Office
